Literature DB >> 1713163

Insulin-like growth factor (IGF) binding to cell monolayers is directly modulated by the addition of IGF-binding proteins.

R H McCusker1, W H Busby, M H Dehoff, C Camacho-Hubner, D R Clemmons.   

Abstract

Insulin-like growth factor-I (IGF-I) binds to specific receptors and IGF-binding proteins (IGFBPs) that are present on cell surfaces. The analysis of [125I]IGF-I binding to human fibroblasts is complicated by IGFBPs on the cell surface and their release into the medium during the binding assay. This release alters the distribution of [125I]IGF-I between type I IGF receptors and both soluble as well as cell surface-associated IGFBPs. In the present study we have determined the effects of three different forms of IGFBPs on [125I]IGF-I binding to cell surface binding sites of human fetal fibroblasts (GM10 cells) and porcine smooth muscle cells. Human 29,000 mol wt (Mr; IGFBP-1), bovine 34,000 Mr (IGFBP-2), and bovine 46,000 Mr (IGFBP-3) forms of IGFBP were compared. Each of the three IGFBPs inhibited [125I]IGF-I binding to the cell surface of both cell types. This effect was due to increased binding of [125I]IGF-I by the IGFBPs in the assay buffer. At equimolar concentrations, IGFBP-3 was more effective than either IGFBP-1 or IGFBP-2 in blocking cell surface binding. The addition of increasing concentrations of unlabeled IGF-I in the presence of each IGFBP showed that either IGFBP-1 or IGFBP-3, but not IGFBP-2, resulted in a paradoxical increase in [125I]IGF-I binding to the cell surface. The paradoxical increase occurred in the presence of excess insulin, indicating that unsaturated type I IGF receptors are not required to demonstrate this phenomenon. In a physiological salt solution, the order of affinity of the IGFBPs for IGF-I was IGFBP-3 greater than IGFBP-1 greater than IGFBP-2. These differences in affinity appear to account for the differences in IGF-I competition for binding that are seen when each of the three proteins is added. Thus, IGFBPs have the potential to alter the partitioning of IGF-I between cell surface-associated IGFBPs, membrane receptors, and the IGFBPs in extracellular fluids. The various forms of IGFBP affect IGF cell surface binding differently, and therefore, each may have distinct effects on IGF target cell actions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1713163     DOI: 10.1210/endo-129-2-939

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

1.  Damage control mechanisms in articular cartilage: the role of the insulin-like growth factor I axis.

Authors:  J A Martin; M B Scherb; L A Lembke; J A Buckwalter
Journal:  Iowa Orthop J       Date:  2000

Review 2.  The insulin-like growth factor binding proteins (IGFBPs) in human breast cancer.

Authors:  J A Figueroa; D Yee
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

3.  Direct measurement of IGF-I and IGFBP-3 in bronchoalveolar lavage fluid from idiopathic pulmonary fibrosis.

Authors:  L Pala; S Giannini; E Rosi; B Cresci; G Scano; S Mohan; R Duranti; C M Rotella
Journal:  J Endocrinol Invest       Date:  2001-12       Impact factor: 4.256

4.  Differential effect of fasting on IGF-BPs in serum of young and adult rats and its implication to impaired skin GAG content.

Authors:  M Cechowska-Pasko; J Pałka
Journal:  Mol Cell Biochem       Date:  2000-02       Impact factor: 3.396

5.  Differential binding and internalization of insulin-like growth factor (IGF)-I in cultured human trophoblast and JEG-3 cells: possible modulatory effect of IGF binding proteins (BP).

Authors:  B Bhaumick; E A Armstrong
Journal:  Endocrine       Date:  1995-09       Impact factor: 3.633

6.  Interaction between the insulin-like growth factor family and the integrin receptor family in tissue repair processes. Evidence in a rabbit ear dermal ulcer model.

Authors:  R D Galiano; L L Zhao; D R Clemmons; S I Roth; X Lin; T A Mustoe
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

7.  Matrix metalloproteinase 19 regulates insulin-like growth factor-mediated proliferation, migration, and adhesion in human keratinocytes through proteolysis of insulin-like growth factor binding protein-3.

Authors:  Thorsten Sadowski; Sebastian Dietrich; Felix Koschinsky; Radislav Sedlacek
Journal:  Mol Biol Cell       Date:  2003-08-22       Impact factor: 4.138

8.  Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP-1.

Authors:  D C Martin; J L Fowlkes; B Babic; R Khokha
Journal:  J Cell Biol       Date:  1999-08-23       Impact factor: 10.539

9.  Zinc alters the kinetics of IGF-II binding to cell surface receptors and binding proteins.

Authors:  Robert H McCusker; Rebecca L Mateski; Jan Novakofski
Journal:  Endocrine       Date:  2003-08       Impact factor: 3.925

10.  Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I.

Authors:  J I Jones; A Gockerman; W H Busby; C Camacho-Hubner; D R Clemmons
Journal:  J Cell Biol       Date:  1993-05       Impact factor: 10.539

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.